The second generation of cell permeable RAS antibody in human IgG1 format (pan-RAS iMab, inRas37) showing favorable PK in vivo with half-life of 3.5 days, only interacts with ATP-bound active RAS mutants but not wild type RAS, attenuates ERK and AKT signaling and suppresses tumor growth in several KRAS mutant (G12D, G12V, G13D, etc.)xenograft models 52. This evidence concerns the gene AKT1 and neoplasm.